- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44 result(s) found for: Medicinal properties.
Displaying page 1 of 3.
EudraCT Number: 2015-002234-53 | Sponsor Protocol Number: eCLEAR-001 | Start Date*: 2016-11-14 | |||||||||||
Sponsor Name:Department of Infectious Diseases, Aarhus University Hospital | |||||||||||||
Full Title: Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a random... | |||||||||||||
Medical condition: HIV persistence during initiation of antiretroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003845-40 | Sponsor Protocol Number: 122-0551-209 | Start Date*: 2019-07-09 | |||||||||||
Sponsor Name:Mayne Pharma LLC | |||||||||||||
Full Title: An open label evaluation of the adrenal suppression potential and pharmacokinetic properties of twice daily halobetasol propionate foam, 0.05% in subjects 12 to less than 18 years of age with plaqu... | |||||||||||||
Medical condition: Plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000783-42 | Sponsor Protocol Number: SDX-PL/001/2016 | Start Date*: 2016-09-19 | |||||||||||
Sponsor Name:Alfa Wassermann Polska Sp. z o.o. | |||||||||||||
Full Title: A phase 3, prospective, open, pilot, monocentric study to evaluate the effect of sulodexide administered at registered dose on morphology and functional properties of the venous endothelium in pati... | |||||||||||||
Medical condition: chronic venous insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000867-65 | Sponsor Protocol Number: C_30990_P1_06 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:Luye Pharma Switzerland AG | |||||||||||||
Full Title: Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed rotigotine-containing transdermal patch in patients with Parkinson's disease | |||||||||||||
Medical condition: Idiopathic Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001651-49 | Sponsor Protocol Number: ALX0171-C201 | Start Date*: 2016-11-07 | |||||||||||
Sponsor Name:Ablynx NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection | |||||||||||||
Medical condition: RSV lower respiratory tract infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) LV (Completed) HU (Completed) ES (Completed) EE (Completed) LT (Completed) SK (Completed) BE (Completed) BG (Completed) CZ (Completed) Outside EU/EEA PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005793-31 | Sponsor Protocol Number: 304001 | Start Date*: 2008-04-16 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A phase II, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 3236 tablets in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostat... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) GB (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001625-10 | Sponsor Protocol Number: 0881X1-4437 | Start Date*: 2008-06-16 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals France | |||||||||||||
Full Title: An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoi... | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Completed) GB (Prematurely Ended) DE (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) DK (Completed) IE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002385-74 | Sponsor Protocol Number: BAY59-7939/17618 | Start Date*: 2015-04-24 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: 7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with catheter-related arterial or venous ... | ||
Medical condition: Catheter related venous or arterial thrombosis | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) AT (Completed) DE (Completed) NL (Completed) PL (Completed) FR (Completed) FI (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003053-21 | Sponsor Protocol Number: M16-560 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arth... | |||||||||||||
Medical condition: Moderate to Severe Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004837-34 | Sponsor Protocol Number: STH17245 | Start Date*: 2014-08-20 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Lung HeXeRT: Advanced proton, hyperpolarised 3helium and 129xenon magnetic resonance imaging for lung cancer radiotherapy planning and evaluation | |||||||||||||
Medical condition: Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002669-20 | Sponsor Protocol Number: 03KET2018 | Start Date*: 2018-09-18 |
Sponsor Name:Celon Pharma SA | ||
Full Title: A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subjects with treatment-resistant bipolar depre... | ||
Medical condition: Eketamine, ketamine’s enantiomer, is designed for use in tretment resistant depression, both unipolar and bipolar. Many publications have demonstrated the effect of ketamine/esketamine (mainly admi... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000640-24 | Sponsor Protocol Number: NP25733 | Start Date*: 2011-08-02 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HC... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001963-22 | Sponsor Protocol Number: 02KET2018 | Start Date*: 2018-08-29 |
Sponsor Name:Celon Pharma SA | ||
Full Title: A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subject with treatment-resistant depression in ... | ||
Medical condition: Eketamine, ketamine’s enantiomer, is designed for use in tretment resistant depression, both unipolar and bipolar. Many publications have demonstrated the effect of ketamine/esketamine (mainly admi... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001542-17 | Sponsor Protocol Number: T109/2019Xe-SAH | Start Date*: 2020-09-17 | |||||||||||
Sponsor Name:Timo Laitio | |||||||||||||
Full Title: Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage | |||||||||||||
Medical condition: Acute rupture of cerebral aneurysm, subarachnoid hemorrhage (SAH), unconsciousness, brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002459-41 | Sponsor Protocol Number: P012-00 | Start Date*: 2012-11-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A multicenter, randomized, partially-blinded, Phase IIb dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings rele... | |||||||||||||
Medical condition: This is the dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings in healthy women | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NO (Completed) DE (Completed) SE (Completed) NL (Completed) HU (Completed) ES (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003781-40 | Sponsor Protocol Number: GCT3014-01 | Start Date*: 2021-01-11 | ||||||||||||||||
Sponsor Name:Genmab A/S | ||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | ||||||||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) FR (Ongoing) NL (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004978-25 | Sponsor Protocol Number: 300 | Start Date*: 2006-09-06 | |||||||||||
Sponsor Name:International Committee for Contraception Research of the Population Council | |||||||||||||
Full Title: A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NE... | |||||||||||||
Medical condition: As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Ongoing) FI (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002069-52 | Sponsor Protocol Number: 4045-301 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SE (Completed) DE (Completed) FR (Ongoing) ES (Trial now transitioned) CZ (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) DK (Trial now transitioned) GR (Completed) NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004429-26 | Sponsor Protocol Number: CMP0119 | Start Date*: 2020-05-08 | |||||||||||
Sponsor Name:PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA | |||||||||||||
Full Title: A multicentre, randomized, open-label, cross-over equivalence study to compare the pharmacodynamic properties, safety, and tolerability of a new combination dry powder of fluticasone propionate and... | |||||||||||||
Medical condition: asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002700-39 | Sponsor Protocol Number: CBAF312D2301 | Start Date*: 2021-09-10 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe... | |||||||||||||
Medical condition: Multiple Sclerosis in pediatric patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) EE (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) LT (Prematurely Ended) AT (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
